A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and active disease clearly documented to have a need to initiate therapy
Has previously untreated CLL/SLL participants without tumor protein 53 (TP53) aberrations and documented 11q status and immunoglobulin heavy chain gene (IGHV) mutational status
The ability to swallow and retain oral medication

Exclusion Criteria:

Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)
Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy
History of severe bleeding disorders
Not adequately recovered from major surgery or has ongoing surgical complications